# Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT

> **NCT04110964** · PHASE1 · UNKNOWN · sponsor: **Libella Gene Therapeutics** · enrollment: 5 (estimated)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** AAV-hTERT

## Key facts

- **NCT ID:** NCT04110964
- **Lead sponsor:** Libella Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-26
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2019-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04110964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04110964, "Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04110964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*